Higher Incidence of Diabetes in Cancer Patients Compared to Cancer-Free Population Controls: A Systematic Review and Meta-Analysis

Simple Summary Diabetes increases the risk of certain types of cancer. However, the literature regarding the incidence of diabetes after cancer diagnosis is inconsistent. We aimed to assess whether there was a higher incidence of diabetes among cancer patients by performing a systematic review and meta-analysis of results from cohort studies. To the best of our knowledge, this review conducted the largest and most up-to-date meta-analysis to compare the incidence of diabetes between cancer patients and the cancer-free population. Our results suggest that new-onset diabetes is positively associated with cancer. Abstract Background: Diabetes increases the risk of certain types of cancer. However, the literature regarding the incidence of diabetes after cancer diagnosis is inconsistent. We aimed to assess whether there was a higher incidence of diabetes among cancer patients by performing a systematic review and meta-analysis of results from cohort studies. Methods: A systematic electronic literature search was carried out from cohort studies regarding the incidence of diabetes in cancer patients, using the databases PubMed (MEDLINE), Embase, Web of Science, and the Cochrane Library. Random-effects meta-analyses were conducted to pool the estimates. Results: A total of 34 articles involving 360,971 cancer patients and 1,819,451 cancer-free controls were included in the meta-analysis. An increased pooled relative risk (RR) of 1.42 (95% confidence interval (CI): 1.30–1.54, I2 = 95, τ2 = 0.0551, p < 0.01) for diabetes in cancer patients was found compared with the cancer-free population. The highest relative risk was observed in the first year after cancer diagnosis (RR = 2.06; 95% CI 1.63–2.60). Conclusions: New-onset diabetes is positively associated with cancer, but this association varies according to cancer type. More prospective studies with large sample sizes and longer follow-up times are advocated to further examine the association and the underlying mechanisms.

[1]  Y. Tang,et al.  Increased risk of diabetes in cancer survivors: a pooled analysis of 13 population-based cohort studies , 2021, ESMO open.

[2]  Weidong Wei,et al.  The Influence of Hormone Therapy on secondary diabetes mellitus in Breast Cancer: A Meta-analysis. , 2021, Clinical breast cancer.

[3]  Shih-Yi Lin,et al.  Risk of diabetes mellitus in patients with prostate cancer receiving injection therapy: A nationwide population‐based propensity score‐matched study , 2021, International journal of clinical practice.

[4]  C. Cook,et al.  Survival and glycemic control in patients with co-existing squamous cell carcinoma and diabetes mellitus , 2021, Future science OA.

[5]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[6]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[7]  T. George,et al.  New onset of type 2 diabetes as a complication after cancer diagnosis: A systematic review , 2020, Cancer medicine.

[8]  Yazhou He,et al.  Risk of Stroke in Cancer Survivors , 2020, Neurology.

[9]  C. Portwine,et al.  42 - The Prevalence of Diabetes Mellitus in Childhood Cancer Survivors: A Systematic Review and Meta-Analysis , 2020 .

[10]  S. Bhatia,et al.  Chronic Comorbidities Among Survivors of Adolescent and Young Adult Cancer , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Jason D. Wright,et al.  Incidence and Predictors of Diabetes Mellitus after a Diagnosis of Early-Stage Breast Cancer in the Elderly Using Real-World Data , 2020, Breast Cancer Research and Treatment.

[12]  A. Blackford,et al.  Burden of comorbidities is higher among elderly survivors of oropharyngeal cancer compared with controls , 2020, Cancer.

[13]  Ken R. Smith,et al.  Long-term diabetes risk among endometrial cancer survivors in a population-based cohort study. , 2019, Gynecologic oncology.

[14]  S. Trestman,et al.  Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma , 2019, BMC Cancer.

[15]  J. Meyerhardt,et al.  Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance) , 2019, JNCI cancer spectrum.

[16]  J. Shaw,et al.  Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. , 2019, Diabetes research and clinical practice.

[17]  M. Salas,et al.  A Retrospective Study of Comorbidities and Complications in Elderly Acute Myeloid Leukemia Patients in the United States. , 2019, Clinical lymphoma, myeloma & leukemia.

[18]  Shyang-Rong Shih,et al.  Increasing risk of diabetes mellitus in postmenopausal women with newly diagnosed primary breast cancer , 2019, Journal of diabetes investigation.

[19]  M. McBride,et al.  Patterns of comorbidities in women with breast cancer: a Canadian population-based study , 2019, Cancer Causes & Control.

[20]  P. Cohen,et al.  Diabetes and Metabolic Syndrome in Survivors of Childhood Cancer , 2019, Hormone Research in Paediatrics.

[21]  J. Derksen,et al.  Monitoring potentially modifiable lifestyle factors in cancer survivors: A narrative review on currently available methodologies and innovations for large-scale surveillance. , 2018, European journal of cancer.

[22]  D. Zylla,et al.  Impact of diabetes and hyperglycemia on health care utilization, infection risk, and survival in patients with cancer receiving glucocorticoids with chemotherapy. , 2018, Journal of diabetes and its complications.

[23]  E. Guallar,et al.  Incidence of Diabetes After Cancer Development: A Korean National Cohort Study , 2018, JAMA oncology.

[24]  D. Roder,et al.  Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study , 2018, Prostate Cancer and Prostatic Diseases.

[25]  Melissa Matz,et al.  Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries , 2018, The Lancet.

[26]  D. Roder,et al.  Comorbidities in Australian women with hormone‐dependent breast cancer: a population‐based analysis , 2018, The Medical journal of Australia.

[27]  Ken R. Smith,et al.  Aging-Related Disease Risks among Young Thyroid Cancer Survivors , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[28]  Ken R. Smith,et al.  Endocrine and Metabolic Diseases among Colorectal Cancer Survivors in a Population-Based Cohort. , 2017, Journal of the National Cancer Institute.

[29]  P. Nathan,et al.  Diabetes Risk in Childhood Cancer Survivors: A Population-Based Study. , 2018, Canadian journal of diabetes.

[30]  S. Buys,et al.  Do cancer survivors develop healthier lifestyle behaviors than the cancer-free population in the PLCO study? , 2017, Journal of Cancer Survivorship.

[31]  J. Goldman,et al.  Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management. , 2016, The oncologist.

[32]  L. Holmberg,et al.  Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer , 2016, International journal of cancer.

[33]  C. Teng,et al.  Outcome and late effects among acute myeloid leukemia survivors: a nationwide population-based study , 2016, Supportive Care in Cancer.

[34]  Jelle J Goeman,et al.  Plea for routinely presenting prediction intervals in meta-analysis , 2016, BMJ Open.

[35]  K. Hirshfield,et al.  Hormonal therapy for breast cancer and diabetes incidence among postmenopausal women. , 2016, Annals of epidemiology.

[36]  P. Austin,et al.  Incidence of Diabetes in Colorectal Cancer Survivors. , 2016, Journal of the National Cancer Institute.

[37]  Ken R. Smith,et al.  Long-term health effects among testicular cancer survivors , 2016, Journal of Cancer Survivorship.

[38]  M. Kelsh,et al.  Racial and Ethnic Variability in the Prevalence and Incidence of Comorbidities Associated with Gastric Cancer in the United States , 2016, Journal of Gastrointestinal Cancer.

[39]  C. Chao,et al.  Long-term Health Outcomes in Survivors of Childhood Cancer Diagnosed Between 1990 and 2000 in a Large US Integrated Health Care System , 2016, Journal of pediatric hematology/oncology.

[40]  Lin Zhao,et al.  Androgen deprivation therapy is associated with diabetes: Evidence from meta‐analysis , 2016, Journal of diabetes investigation.

[41]  P. Porporato Understanding cachexia as a cancer metabolism syndrome , 2016, Oncogenesis.

[42]  Min Yu,et al.  Depression and Risk for Diabetes: A Meta-Analysis. , 2015, Canadian journal of diabetes.

[43]  Sun Shengrong,et al.  Clinical pathological characteristics of breast cancer patients with secondary diabetes after systemic therapy: a retrospective multicenter study , 2015, Tumor Biology.

[44]  E. D. de Vries,et al.  Cancer-drug induced insulin resistance: innocent bystander or unusual suspect. , 2015, Cancer treatment reviews.

[45]  H. Sørensen,et al.  Relative mortality rates from incident chronic diseases among breast cancer survivors--a 14 year follow-up of five-year survivors diagnosed in Denmark between 1994 and 2007. , 2015, European journal of cancer.

[46]  Kevin A. Henry,et al.  Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State , 2015, Journal of the National Cancer Institute.

[47]  F Levi,et al.  European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  J. Ioannidis,et al.  Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies , 2015, BMJ : British Medical Journal.

[49]  C. Kao,et al.  Association of tamoxifen use and increased diabetes among Asian women diagnosed with breast cancer , 2014, British Journal of Cancer.

[50]  T. Lash,et al.  Incident comorbidities and all-cause mortality among 5-year survivors of Stage I and II breast cancer diagnosed at age 65 or older: a prospective-matched cohort study , 2014, Breast Cancer Research and Treatment.

[51]  C. O’Malley,et al.  Prevalence and incidence of comorbidities in elderly women with ovarian cancer. , 2013, Gynecologic oncology.

[52]  Geoff M. Anderson,et al.  Incidence of diabetes among postmenopausal breast cancer survivors , 2013, Diabetologia.

[53]  M. Schlumberger,et al.  Radiation dose to the pancreas and risk of diabetes mellitus in childhood cancer survivors: a retrospective cohort study. , 2012, The Lancet. Oncology.

[54]  D. Glass,et al.  Cancer cachexia: mediators, signaling, and metabolic pathways. , 2012, Cell metabolism.

[55]  R. Herings,et al.  Occurrence of Comorbidities before and after Soft Tissue Sarcoma Diagnosis , 2012, Sarcoma.

[56]  F. Granath,et al.  Evaluation of prevalent and incident ovarian cancer co-morbidity , 2012, British Journal of Cancer.

[57]  A. Shukla,et al.  Comorbidities and Concomitant Medication Use in Men with Prostate Cancer or High Levels of PSA Compared to Matched Controls: A GPRD Analysis , 2012, Journal of cancer epidemiology.

[58]  R. Herings,et al.  Prevalence and incidence of acute and chronic comorbidity in patients with squamous cell carcinoma of the head and neck , 2012, Head & neck.

[59]  H. Seo,et al.  Metabolic syndrome in adult cancer survivors: a meta-analysis. , 2012, Diabetes research and clinical practice.

[60]  D. Forman,et al.  Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study , 2011, British Journal of Cancer.

[61]  C. O’Malley,et al.  An observational study of the prevalence and incidence of comorbid conditions in older women with breast cancer , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[62]  J. Stanford,et al.  Diabetes mellitus and health‐related quality of life in prostate cancer: 5‐year results from the Prostate Cancer Outcomes Study , 2011, BJU international.

[63]  N. Keating,et al.  Gonadotropin-Releasing Hormone Agonists and the Risks of Type 2 Diabetes and Cardiovascular Disease in Men with Prostate Cancer , 2011, Drugs.

[64]  Richard D Riley,et al.  Interpretation of random effects meta-analyses , 2011, BMJ : British Medical Journal.

[65]  J. Danesh,et al.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies , 2010, The Lancet.

[66]  D. Harlan,et al.  Diabetes and Cancer , 2010, Diabetes Care.

[67]  Edward Giovannucci,et al.  Diabetes and Cancer , 2010, Diabetes Care.

[68]  G. Hotamisligil,et al.  Mechanisms of TNF-alpha-induced insulin resistance. , 2009 .

[69]  Mika Kivimäki,et al.  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study , 2009, The Lancet.

[70]  Gerta Rücker,et al.  Bmc Medical Research Methodology Open Access Undue Reliance on I 2 in Assessing Heterogeneity May Mislead , 2022 .

[71]  S. Basaria Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth. , 2008, Journal of andrology.

[72]  M. Sydes,et al.  Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.

[73]  N. Aziz Cancer survivorship research: State of knowledge, challenges and opportunities , 2007, Acta oncologica.

[74]  D. Elahi,et al.  Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. , 2005, The Journal of clinical endocrinology and metabolism.

[75]  A. Munshi,et al.  Weight Loss During Radiotherapy for Head and Neck Malignancies: What Factors Impact It? , 2003, Nutrition and cancer.

[76]  R. Schots,et al.  Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation , 2003, Leukemia.

[77]  Z. Bloomgarden,et al.  Inflammation and insulin resistance. , 2003, Diabetes care.

[78]  T. Okamura,et al.  Kinetics of plasma cytokines after hematopoietic stem cell transplantation from unrelated donors: the ratio of plasma IL-10/sTNFR level as a potential prognostic marker in severe acute graft-versus-host disease , 2001, Bone Marrow Transplantation.

[79]  L. Robison,et al.  Changes in body mass index and prevalence of overweight in survivors of childhood acute lymphoblastic leukemia: role of cranial irradiation. , 2000, Medical and pediatric oncology.

[80]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[81]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.

[82]  R. Bergman,et al.  Insulin action and metabolism in patients with head and neck cancer , 1991, Cancer.

[83]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[84]  J. Sundquist,et al.  Risk of coronary heart disease in patients with cancer: a nationwide follow-up study from Sweden. , 2012, European journal of cancer.

[85]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[86]  M. Extermann,et al.  Interaction between comorbidity and cancer. , 2007, Cancer control : journal of the Moffitt Cancer Center.